GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas
    Oxford University Press (OUP) ; 2013
    In:  European Journal of Endocrinology Vol. 169, No. 3 ( 2013-09), p. 359-366
    Details
    In: European Journal of Endocrinology, Oxford University Press (OUP), Vol. 169, No. 3 ( 2013-09), p. 359-366
    Abstract: Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease before and after 24 and 60 months of continuous treatment with CAB only in patients with hyperprolactinemia. Subjects and methods Forty patients (11 men and 29 women, aged 38.7±12.5 years) newly diagnosed with hyperprolactinemia entered the study. Cumulative CAB dose ranged from 12 to 588 mg (median 48 mg) at 24 months and 48–1260 mg (median 149 mg) at 60 months. All patients underwent a complete trans-thoracic echocardiographic examination. Valve regurgitation was assessed according to the American Society of Echocardiography. Results At baseline, the prevalence of trace mitral, aortic, pulmonic, and tricuspid regurgitations was 20, 2.5, 10, and 40% respectively, with no patient showing clinically relevant valvulopathy. After 24 months, no change in the prevalence of trace mitral ( P =0.78) and pulmonic ( P =0.89) regurgitations and of mild aortic ( P =0.89) and tricuspid ( P =0.89) regurgitations was found when compared with baseline. After 60 months, the prevalence of trace tricuspid regurgitation was only slightly increased when compared with that after 24 months (37.5%; P =0.82), but none of the patients developed significant valvulopathy. No correlation was found between cumulative dose and prevalence or grade of valve regurgitation at both evaluations. Prolactin levels normalized in all patients but one. Conclusion CAB does not increase the risk of significant cardiac valve regurgitation in prolactinomas after the first 5 years of treatment.
    Type of Medium: Online Resource
    ISSN: 0804-4643 , 1479-683X
    URL: Article
    DOI: 10.1530/EJE-13-0231
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 1485160-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission
    Oxford University Press (OUP) ; 2010
    In:  European Journal of Endocrinology Vol. 162, No. 6 ( 2010-06), p. 1035-1042
    Details
    In: European Journal of Endocrinology, Oxford University Press (OUP), Vol. 162, No. 6 ( 2010-06), p. 1035-1042
    Abstract: The GH/insulin-like growth factor 1 axis is physiologically involved in the regulation of electrolytes and water homeostasis by kidneys, and influences glomerular filtration and tubular re-absorption processes. The aim of the study was to investigate renal structure and function in acromegalic patients during active disease and disease remission. Patients Thirty acromegalic patients (15 males and 15 females), aged 32–70 years, were enrolled for the study. Ten de novo patients had active disease, whereas 20 patients showed disease remission 1 year after medical treatment with somatostatin analogs (SA) (ten patients) or surgery (ten patients). Thirty healthy subjects matched for age, gender, and body surface area were enrolled as controls. Results In both active (A) and controlled (C) patients, creatinine clearance ( P 〈 0.001) and citrate ( P 〈 0.05) and oxalate levels ( P 〈 0.001) were higher, whereas filtered Na ( P 〈 0.001) and K ( P 〈 0.001) fractional excretions were lower than those in the controls. Urinary Ca ( P 〈 0.001) and Ph ( P 〈 0.05) levels were significantly increased compared with the controls, and in patients with disease control, urinary Ca ( P 〈 0.001) levels were significantly reduced compared with active patients. Microalbuminuria was significantly increased in active patients ( P 〈 0.05) compared with controlled patients and healthy control subjects. The longitudinal ( P 〈 0.05) and transverse ( P 〈 0.05) diameters of kidneys were significantly higher than those in the controls. In all patients, the prevalence of micronephrolithiasis was higher than that in the controls ( P 〈 0.001), and was significantly correlated to disease duration ( r =0.871, P 〈 0.001) and hydroxyproline values ( r =0.639, P 〈 0.001). Conclusions The results of the current study demonstrated that acromegaly affects both renal structure and function. The observed changes are not completely reversible after disease remission.
    Type of Medium: Online Resource
    ISSN: 0804-4643 , 1479-683X
    URL: Article
    DOI: 10.1530/EJE-10-0007
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Oxford University Press (OUP)
    Publication Date: 2010
    detail.hit.zdb_id: 1485160-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal
    Oxford University Press (OUP) ; 2010
    In:  European Journal of Endocrinology Vol. 162, No. 5 ( 2010-05), p. 993-999
    Details
    In: European Journal of Endocrinology, Oxford University Press (OUP), Vol. 162, No. 5 ( 2010-05), p. 993-999
    Abstract: Somatostatin analogs (SA) are the cornerstone in the medical treatment of acromegaly, used as either primary or adjunctive therapy. In particular, SA are effective in inducing the biochemical remission of the disease and tumor shrinkage, although only few cases of complete disappearance of the pituitary tumor in patients treated with SA as long-acting formulations have been reported. SA withdrawal has been demonstrated to keep safe levels of GH and IGF1 at least in a small subset of patients well responsive to SA, although it is generally followed by disease recurrence after several months. Case report A 61-year-old female patient bearing a very large GH-secreting pituitary macroadenoma was treated with 12-month lanreotide Autogel (ATG), at the initial dose of 120 mg/28 days. After 3 months, GH and IGF1 levels were fully normalized, to prolong the administration interval from 28 to 56 days. After 6 months of treatment, a significant tumor shrinkage (90% of baseline size) was observed, whereas GH and IGF1 excess was still well controlled. After 12-month therapy, a complete disappearance of the pituitary tumor was observed, and the hormonal evaluation confirmed the complete biochemical remission of acromegaly. Lanreotide ATG treatment was withdrawn. The clinical, biochemical, and radiological remission of acromegaly was maintained 24 months after lanreotide ATG treatment discontinuation, without evidence of disease recurrence. Conclusions This report represents an exemplary case of the potentiality of treatment with lanreotide ATG in inducing a complete remission of acromegalic disease, persistent after a long period of time from treatment withdrawal.
    Type of Medium: Online Resource
    ISSN: 0804-4643 , 1479-683X
    URL: Article
    DOI: 10.1530/EJE-09-0769
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Oxford University Press (OUP)
    Publication Date: 2010
    detail.hit.zdb_id: 1485160-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects
    Oxford University Press (OUP) ; 2008
    In:  European Journal of Endocrinology Vol. 159, No. 4 ( 2008-10), p. 389-397
    Details
    In: European Journal of Endocrinology, Oxford University Press (OUP), Vol. 159, No. 4 ( 2008-10), p. 389-397
    Abstract: In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality. Objective To investigate the relationships between IGF1 levels, blood pressure (BP), and glucose tolerance (GT). Subjects Four-hundred and four subjects (200 men aged 18–80 years). Exclusion criteria: personal history of pituitary or cardiovascular diseases; previous or current treatments with drugs interfering with BP, GT, or lipids, corticosteroids ( 〉 2 weeks), estrogens, or testosterone ( 〉 12 weeks); smoking of 〉 15 cigarettes/day and alcohol abuse ( 〉 3 glasses of wine/day). Results Two hundred and ninety-six had normal BP (73.3%), 86 had mild (21.3%), and 22 had severe (5.4%) hypertension; 322 had normal GT (NGT (79.7%)), 53 had impaired glucose tolerance (IGT (13.1%)), 29 had diabetes mellitus (7.2%). Normotensive subjects had significantly higher IGF1 levels (0.11±0.94 SDS) than those with mild (−0.62±1.16 SDS, P 〈 0.0001) or severe (−1.01±1.07 SDS, P 〈 0.0001) hypertension. IGF1 SDS ( t =−3.41, P =0.001) independently predicted systolic and diastolic BP ( t =−2.77, P =0.006) values. NGT subjects had significantly higher IGF1 levels (0.13±0.90 SDS) than those with IGT (−0.86±1.14 SDS, P 〈 0.0001) or diabetes mellitus (−1.31±1.13 SDS, P 〈 0.0001). IGF1 SDS independently predicted fasting glucose ( t =−3.49, P =0.0005) and homeostatic model assessment (HOMA)-R ( t =−2.15, P =0.033) but not insulin ( t =−1.92, P =0.055) and HOMA-β ( t =−0.19, P =0.85). Conclusion IGF1 levels in the low normal range are associated with hypertension and diabetes in subjects without pituitary and cardiovascular diseases.
    Type of Medium: Online Resource
    ISSN: 0804-4643 , 1479-683X
    URL: Article
    DOI: 10.1530/EJE-08-0201
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Oxford University Press (OUP)
    Publication Date: 2008
    detail.hit.zdb_id: 1485160-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias
    Oxford University Press (OUP) ; 2013
    In:  European Journal of Endocrinology Vol. 168, No. 1 ( 2013-01), p. 15-22
    Details
    In: European Journal of Endocrinology, Oxford University Press (OUP), Vol. 168, No. 1 ( 2013-01), p. 15-22
    Abstract: To evaluate the effects of short- and long-term treatment with pegvisomant (PEG) on arrhythmias in acromegalic patients resistant to long-term, high-dose therapy with somatostatin analogs (SA). Materials and methods Thirteen patients entered the study. All patients started PEG at initial dose of 10 mg daily and then titrated to 5 mg every 6 weeks on the basis of IGF1. A standard 24-h electrocardiography registration was performed in all patients at baseline and after 6 and 18 months of PEG to evaluate: mean (HR), maximum (MHR), and minimum (mHR) heart rate; pauses number (P) and duration (PD); supraventricular episodes (SEs) number and duration (SED); and ventricular ectopic beats (EB) number and duration (EBD). Left ventricular mass (LVM) was also evaluated by standard echocardiography. Results A slight but not significant decrease in HR, MHR, and mHR was observed after 6-month PEG, whereas a significant decrease in HR ( P =0.03), MHR ( P =0.05), and mHR ( P =0.05) was found after 18-month PEG compared with baseline. LVM significantly ( P =0.05) correlated with MRH ( r =−0.50) after short-term treatment, and with HR ( r =−0.54) and mHR ( r =−0.55) after long-term treatment. Long-term PEG induced the complete recovery of arrhythmias recorded at baseline in one patient and the improvement of rhythm disorders developed after 6-month therapy in another patient. The prevalence of conduction disturbances passed from 15 to 7.7% after long-term PEG. Conclusions Long-term treatment with PEG reduces HR, MHR, and mHR and improves rhythm abnormalities in acromegaly.
    Type of Medium: Online Resource
    ISSN: 0804-4643 , 1479-683X
    URL: Article
    DOI: 10.1530/EJE-12-0596
    RVK:
    WA 15000
    Language: Unknown
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 1485160-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...